Corinne Danan is the General Manager, Biopharma, at Veracyte. Ms. Danan leads the company’s offerings to biopharmaceutical companies, bringing more than 30 years of executive experience in the pharmaceutical, life sciences and healthcare industries, as well as strong leadership in Commercial Operations, to her role at Veracyte.
She co-founded and was a member of the board of HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. At HalioDx, Ms. Danan led the creation and development of the pharmaceutical business unit, bringing to the company’s biopharmaceutical partners various solutions to support better understanding of the tumor microenvironment within different phases of clinical trials.
Prior to HalioDx, Ms. Danan held senior positions at leading diagnostics companies, including Qiagen, where she was Head of Market Development and Management in EMEA; Ipsogen, where she served as Vice President of Commercial Operations; and Monogram Biosciences, where she was the European Union General Manager. Earlier in her career, she held various leadership positions at Eli Lilly.
Ms. Danan holds an M.B.A. from INSEAD Business School (France).